ADA-011 is under clinical development by Adanate and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADA-011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADA-011 is under development for the treatment of solid tumor. The drug candidate acts by targeting leukocyte immunoglobulin-like receptor (LILRB). It is administered through intravenous route.
Adanate operates as a biotechnology company developing immunotherapies that help the immune system to fight cancer. Its technology is based on the immune-regulating capacity of a family of receptors called leukocyte immunoglobulin-like receptor B (LILRBs) that develop antibody drug candidates to enhance innate and adaptive immunity cells. Adanate’s antibody therapeutics blocks the inhibitory function of the LILRB’s that facilitate the activity of both innate and adaptive immunity to destroy the cancer cells and combat infectious and auto-immune diseases. Adanate is headquartered in La Jolla, California, the US.
For a complete picture of ADA-011’s drug-specific PTSR and LoA scores, buy the report here.